Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

被引：69
|
作者：
Merin, Noah M. [1 ]
Kelly, Kevin R. [1 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Internal Med, Los Angeles, CA 90033 USA
来源：
PHARMACEUTICALS | 2015年 / 8卷 / 01期
关键词：
multiple myeloma; proteasome inhibitors; toxicity;
D O I：
10.3390/ph8010001
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
引用
收藏
页码：1 / 20
页数：20
相关论文
共 50 条
  • [21] The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors
    Alkharabsheh, Omar
    Sidiqi, M. Hasib
    Aljama, Mohammed A.
    Gertz, Morie A.
    Frankel, Arthur E.
    [J]. ACTA HAEMATOLOGICA, 2020, 143 (02) : 118 - 123
  • [22] Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma
    Diamond, Benjamin
    Rossi, Adriana C.
    Pearse, Roger N.
    Jayabalan, David
    Perry, Arthur
    Pekle, Karen
    Mark, Tomer
    Niesvizky, Ruben
    [J]. BLOOD, 2016, 128 (22)
  • [23] Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma
    Ferrarini, M.
    Ferrero, E.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2011, 18 (34) : 5185 - 5195
  • [24] Oxidative stress and proteasome inhibitors in multiple myeloma
    Lipchick, Brittany C.
    Fink, Emily E.
    Nikiforov, Mikhail A.
    [J]. PHARMACOLOGICAL RESEARCH, 2016, 105 : 210 - 215
  • [25] Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma
    Kashiwazaki, Sho
    Kamiko, Satoshi
    Uozaki, Ryo
    Yamamoto, Tomofumi
    Ichikawa, Daiju
    Hattori, Yutaka
    Matsushita, Maiko
    Hirao, Maki
    Kunieda, Hisako
    Yamazaki, Kohei
    [J]. BLOOD, 2018, 132
  • [26] Second Generation Proteasome Inhibitors in Multiple Myeloma
    Gozzetti, Alessandro
    Papini, Giulia
    Candi, Veronica
    Brambilla, Corrado Zuanelli
    Sirianni, Santina
    Bocchia, Monica
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (07) : 920 - 926
  • [27] Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma
    Zhang, Wen
    Wang, Xueyuan
    Zhang, Haoyang
    Wen, Tiantian
    Yang, Lin
    Miao, Hang
    Wang, Jia
    Liu, Hailong
    Yang, Xu
    Lei, Meng
    Zhu, Yongqiang
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 40
  • [28] Proteasome inhibitor for treatment of multiple myeloma
    Ahmad, K
    [J]. LANCET ONCOLOGY, 2005, 6 (08): : 546 - 546
  • [29] Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma
    Cole, Daniel C.
    Frishman, William H.
    [J]. CARDIOLOGY IN REVIEW, 2018, 26 (03) : 122 - 129
  • [30] Proteasome inhibitors in multiple myeloma: 10 years later
    Moreau, Philippe
    Richardson, Paul G.
    Cavo, Michele
    Orlowski, Robert Z.
    San Miguel, Jesus F.
    Palumbo, Antonio
    Harousseau, Jean-Luc
    [J]. BLOOD, 2012, 120 (05) : 947 - 959
12345